loading page

Vitamin D as an adjuvant therapy in Neonatal Bronchopulmonary Dysplasia: is it beneficial?
  • Mohamed Elfarargy,
  • Ghada Al-Ashmawy
Mohamed Elfarargy
Tanta University Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Ghada Al-Ashmawy
Tanta University Faculty of Pharmacy
Author Profile

Abstract

Background: Neonatal bronchopulmonary dysplasia (BPD) is a chronic neonatal respiratory disease that is caused by prolonged oxygenation and mechanical ventilation (MV), leading to respiratory distress (RD). Patients and methods: Prospective randomized controlled trial (RCT) with identification number TCTR20210622001 which was done at Tanta University Hospital (TUH) from August 2016 to February 2018 on 100 premature neonates who had RD and were put on MV. The examined neonates were classified into 2 groups: group 1, which received vitamin D supplementation, and group 2, which had placebo. Urinary β2-microglobulin (B2M) in addition to serum Krebs von den Lungen-6 (KL-6) levels were measured on the 1st and the14th day of hospitalization. Results: Significant decrease in urinary B2M and serum KL-6 levels in neonates of group 1 who were received vitamin D, if compared with group 2 neonates, who had taken placebo (P < 0.05). There was a significant decrease in the time of hospital stay in group 1 neonates, if compared with group 2 neonates (P < 0.05). Group 1 neonates showed a significant decrease of the developed BPD cases, if compared with group 2 (P < 0.05). Conclusion: Vitamin D supplementation may help in the prevention of BPD in neonates. Recommendation: Routine vitamin D supplementation to preterm neonates who are susceptible to develop BPD.